The positivity of PD-L2 significantly indicated clinical response to pembrolizumab on combined tumor, while stromal immune cells’ T cell immunoglobulin mucin-3 (Tim-3) antibodies have curative effects in laboratory-scale studies in several tumors (Yearley et al., 2017; Liu et al., 2018). This evidence concerns the gene PDCD1LG2 and neoplasm.